Yasuhiro Kikuchi
YOU?
Author Swipe
View article: Myeloid Cell Adhesion Molecule 1 (CADM1) Promotes Proinflammatory Signaling in Human Inflammatory Bowel Diseases
Myeloid Cell Adhesion Molecule 1 (CADM1) Promotes Proinflammatory Signaling in Human Inflammatory Bowel Diseases Open
CADM1 is a mediator of proinflammatory signaling cascades in the colon and a potential therapeutic target for the IBDs.
View article: Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study
Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study Open
Not applicable.
View article: Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study
Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study Open
PBT achieving 67.5 Gy combined with standard chemotherapy showed excellent local control for unresectable LAPC. Total irradiation dose, tumor site, and PS score at an initial diagnosis could be important prognostic factors. In this study, …
View article: Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation
Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation Open
The aim of the present study was to report the feasibility of proton beam reirradiation for patients with locally recurrent rectal cancer (LRRC) with prior pelvic irradiation. The study population included patients who were treated with pr…
View article: Preliminary Investigation of the Efficacy and Indications of Proton Beam Therapy for Stage IV Pancreatic Adenocarcinoma
Preliminary Investigation of the Efficacy and Indications of Proton Beam Therapy for Stage IV Pancreatic Adenocarcinoma Open
PBT is indicated when the number of metastases is limited to ≤ 4 lesions and all tumors can be irradiated within the smallest possible number of irradiation fields that can be performed within the patient's tolerable time, which is a subje…
View article: Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer
Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer Open
Local treatment of oligometastatic esophagogastric cancer has been reported to improve overall survival (OS) compared to systemic therapy alone. This study evaluated the feasibility and safety of proton beam therapy (PBT) for the treatment…
View article: Proton beam therapy for gliomas: a multicenter prospective registry study from all proton beam facilities in Japan
Proton beam therapy for gliomas: a multicenter prospective registry study from all proton beam facilities in Japan Open
We reviewed the outcomes of glioma patients enrolled in a prospective observational registry study of proton beam therapy (PBT) in Japan. The inclusion criteria were glioma patients registered in the Electronic Data Capture system, the Pro…
View article: Table S10 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S10 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S10
View article: Table S3 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S3 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S3
View article: Figure S1-S7 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Figure S1-S7 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Figures S1-S7
View article: Table S1 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S1 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S1
View article: Figure S1-S7 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Figure S1-S7 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Figures S1-S7
View article: Table S11 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S11 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S11
View article: Table S5 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S5 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S5
View article: Data from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Data from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
CD8+ T cells recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathologic conditions such as cancer. Advances in proteogenomic analysis of HLA ligandomes have demonstrated that cells present a subset of cry…
View article: Supplementary Legends from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Supplementary Legends from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Supplementary Information
View article: Table S4 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S4 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S4
View article: Table S9 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S9 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S9
View article: Data from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Data from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
CD8+ T cells recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathologic conditions such as cancer. Advances in proteogenomic analysis of HLA ligandomes have demonstrated that cells present a subset of cry…
View article: Table S10 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S10 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S10
View article: Table S8 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S8 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S8
View article: Table S3 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S3 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S3
View article: Table S9 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S9 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S9
View article: Table S1 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S1 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S1
View article: Table S2 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S2 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S2
View article: Table S6 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S6 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S6
View article: Table S11 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S11 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S11
View article: Table S7 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i>
Table S7 from CD8<sup>+</sup> T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA <i>PVT1</i> Open
Table S7